In memoriam: Frank F. Davis
Frank F. Davis, a biochemist who 50 years ago came up with pegylation, a drug delivery system now used in mRNA vaccines, died May 19, 2021. He was 100.
Davis knew that little changes make a big difference.
Some medicines are so conspicuous, or so obviously not part of the human body, that the immune system attacks them before they have a chance to do much. Others are so small that the kidneys clear them from the bloodstream in a couple of days.

Davis had to attach drugs to a long, water-loving molecule such as polyethylene glycol, or PEG.
When attached to lipids, PEG helps coat drugs in an oily layer that water then surrounds, so the kidneys don’t quickly purge the body of its medicine. And, since the edge of cells are made of lipids, a cell is more likely to say, “Come right in.”
PEG has been used to deliver cancer drugs and to treat what’s known as “bubble boy disease” (an immune deficiency so severe that even a small infection can kill), and is now in the mRNA vaccines against COVID-19. (Some people have an allergy to PEG; the they ask their doctor about the availability of different vaccines.)
Interviewed by the in 2001, Davis said, “I have a great feeling of satisfaction that something I did finally worked out.” He had the idea with former graduate student Abraham Abuchowski in 1979 and started a company in the 1980s, before others became convinced. In his final year, he against a host of diseases, reducing infant mortality in the U.S. from one in 10 in 1900 to less than one in 100 in 2000.
You could say that Davis was a scientific hipster. He studied nucleic acids , he made his own sourdough (little changes make a big difference), and he never got a smartphone. Almost 20 years before mRNA vaccines, he wrote that he was “deeply impressed and indeed humbled by how pegnology has grown.”
Davis came from a poor background and had a wealth of experience before he became a scientist. Born in Pendleton, Oregon, July 23, 1920, he left his grandfather’s farm after a childhood and repaired planes as a mechanic in World War II. With the G.I. Bill he enrolled in a chemistry program in Hawaii, completing his doctorate in biochemistry at Berkeley in his mid-30s. It was “the first time in his life that he was challenged at the right level,” daughter Ann . He later moved to Rutgers as a professor of agricultural biochemistry because Berkeley didn’t consider people over age 29 for tenure track.
He is survived by his daughter, Ann; his son, Paul; and six grandchildren and great grandchildren.
Davis, whose research extended the lifespan of treatments, seems to have lived an extended life himself.Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

2025 ASBMB election results
Learn about the new president, secretary, Council members and committee members.

2025 PROLAB awardees announced
Seven early-career scientists receive grants to advance their research by working in North American labs.

Yu receives early career research award
He will receive $35,000 to fund his research on the proteotype and cell signaling.

Neurobiology of stress and substance use
MOSAIC scholar and proud Latino, Bryan Cruz of Scripps Research Institute studies the neurochemical origins of PTSD-related alcohol use using a multidisciplinary approach.

Hargrove recognized for leadership
He is among more than 50 individuals from the Iowa State University College of Liberal Arts and Sciences to receive recognition for their departmental dedication and contributions.

Teach, learn & transform biochemistry education
Meet the co-chairs of the 2025 ASBMB meeting on reimagining undergraduate education in the molecular life sciences to be held July 24–27, 2025 in St. Paul, Minnesota.